



This is a repository copy of *Public health economic modelling in evaluations of salt and/or alcohol policies: a systematic scoping review*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/221604/>

Version: Published Version

Article:

Mensah, J.P. orcid.org/0009-0001-7664-8458, Thomas, C., Akparibo, R. orcid.org/0000-0003-3751-2432 et al. (1 more author) (2025) Public health economic modelling in evaluations of salt and/or alcohol policies: a systematic scoping review. BMC Public Health, 25 (1). 82. ISSN 1471-2458

<https://doi.org/10.1186/s12889-024-21237-7>

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

RESEARCH

Open Access



Public health economic modelling in evaluations of salt and/or alcohol policies: a systematic scoping review

Joseph Prince Mensah^{1*}, Chloe Thomas¹, Robert Akparibo¹ and Alan Brennan¹

Abstract

Background Public health economic modelling is an approach capable of managing the intricacies involved in evaluating interventions without direct observational evidence. It is used to estimate potential long-term health benefits and cost outcomes. The aim of this review was to determine the scope of health economic models in the evaluation of salt and/or alcohol interventions globally, to provide an overview of the literature and the modelling methods and structures used.

Methods Searches were conducted in Medline, Embase, and EconLit, and complemented with citation searching of key reviews. The searches were conducted between 13/11/2022 and 8/11/2023, with no limits to publication date. We applied a health economic search filter to select model-based economic evaluations of public health policies and interventions related to alcohol consumption, dietary salt intake, or both. Data on the study characteristics, modelling approaches, and the interventions were extracted and synthesised.

Results The search identified 1,958 articles, 82 of which were included. These included comparative risk assessments (29%), multistate lifetables (27%), Markov cohort (22%), microsimulation (13%), and other (9%) modelling methods. The included studies evaluated alcohol and/or salt interventions in a combined total of 64 countries. Policies from the UK (23%) and Australia (18%) were the most frequently evaluated. A total of 58% of the models evaluated salt policies, 38% evaluated alcohol policies, and only three (4% of included modelling studies) evaluated both alcohol- and salt-related policies.

The range of diseases modelled covered diabetes and cardiovascular disease-related outcomes, cancers, and alcohol-attributable harm. Systolic blood pressure was a key intermediate risk factor in the excessive salt-to-disease modelling pathway for 40 (83%) of the salt modelling studies. The effects of alcohol consumption on adverse health effects were modelled directly using estimates of the relative risk of alcohol-attributable diseases.

Conclusions This scoping review highlights the substantial utilisation of health economic modelling for estimating the health and economic impact of interventions targeting salt or alcohol consumption. The limited use of combined alcohol and salt policy models presents a pressing need for models that could explore their integrated risk factor pathways for cost-effectiveness comparisons between salt and alcohol policies to inform primary prevention policymaking.

*Correspondence:

Joseph Prince Mensah
jpmensah1@sheffield.ac.uk

Full list of author information is available at the end of the article



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Keywords Modelling, Salt, Sodium reduction, Alcohol, Scoping review, Non-communicable diseases, Cardiovascular disease

Background

Non-communicable diseases (NCDs), such as cardiovascular diseases (CVDs) and cancers, are caused, to some extent, by modifiable risk factors such as unhealthy diets, excessive salt intake, harmful use of alcohol, and physical inactivity [1]. The excessive intake of dietary salt accounts for a large increase in hypertension prevalence since it is associated with an increase in systolic blood pressure [2]. The unhealthy consumption of alcohol has also previously been linked to acute and chronic changes in systolic blood pressure, and studies suggest that alcohol consumption can cause hypertension in heavy drinkers [3]. These two diet-related risk factors for hypertension and non-communicable diseases are therefore responsible for significant health and economic burden globally [1]. One way to reduce this burden is by implementing public health policies to control the consumption of these risk factors in the population [1, 4].

Health economic modelling has widely been used to generate scientific evidence on the costs and outcomes of dietary salt-reduction interventions and alcohol policies, aiding the evaluation and planning of dietary and other public health strategies [5]. Recent reviews have focused on health economic models for population-level dietary policies or alcohol policies, offering policymakers an overview of available health economic models to adapt or implement [6–8]. However, some of these reviews have excluded interventions at the primary care level and have not examined models addressing both salt and alcohol together. To our knowledge, no review has comprehensively explored the scope of health economic models evaluating policies targeting excessive dietary salt intake, alcohol consumption, or both. Identifying and understanding the scope of models addressing both salt and alcohol consumption will support the evaluation of interventions for efficient resource allocation and priority setting, while offering insights into common modelling approaches and health outcomes to inform the development of joint models targeting both risk factors.

This study systematically reviews the literature to identify health economic modelling studies evaluating public health interventions or policies targeting the harmful alcohol use and/or excessive intake of dietary salt. The aim is to assess the global scope and volume of these studies, provide an overview of their modelling structures, and analyse the role of intermediate risk factors in the modelling of salt or alcohol consumption to related health outcomes.

Methods

Study design

The scoping review was conducted following the reporting standards in the PRISMA extension for scoping reviews (PRISMA-ScR) [9]. A systematic scoping review aims to “map the key concepts underpinning a research area and the main sources and types of evidence available” [10]. For this scoping review, we defined public health economic models as decision analytic models or mathematical tools used in economic evaluations to compare and synthesise evidence on costs and health benefits [11].

Search strategy

A comprehensive search strategy was developed and used to identify all potentially relevant peer-reviewed studies published in English. The search strategy was tested, refined and subsequently used to conduct systematic searches in the following electronic databases: Medline, EMBASE (via Ovid), and EconLit (via Ovid). The search was first performed on 13/11/2022, with an update search conducted on 8/11/2023 (see Additional file 1). The search covered publications from 01 January 1990 to the updated search date (i.e., 8/11/2023). The search terms utilised four broad categories of terms, combined using Boolean operators: (salt OR alcohol) AND economic evaluation AND modelling. The search terms used were complemented by MeSH terms, and the NHS CRD EED search filter for economic evaluation [12] was applied in the Medline and EMBASE searches.

The search records were imported into the Covidence reviewing tool by Cochrane for screening. Two reviewers (JPM, JO) independently screened all titles and abstracts of the identified studies against the inclusion criteria, and discrepancies were resolved by consensus. The full texts of the remaining studies were subsequently assessed to determine their eligibility for inclusion. Citation searches of five key reviews [6–8, 13, 14], as well as the reference lists of the included studies, were scanned to identify studies that were missed following the database searches.

Inclusion and exclusion criteria

A study was deemed eligible for inclusion if it was a model-based full health economic evaluation, i.e., a comparative analysis of alternative health interventions/policies in terms of both costs and consequences [15]. We considered population-level and individual lifestyle interventions or policies aimed at reducing the harmful

consumption of alcohol, dietary salt, or both unhealthy dietary behaviours in any defined human population globally.

Conversely, studies were excluded based on the following criteria:

1. Economic evaluations were based on empirical trials, i.e., within-trial or alongside randomised controlled trials (RCTs).
2. Evaluations of pharmacological interventions, medical devices or procedures, or diagnostic tests.
3. Epidemiological models that evaluate only the burden of disease with no cost or health economic outcomes.
4. Cost analysis studies that do not examine the consequences or health-related outcomes.
5. Non-English language studies.

Data extraction and synthesis

A pair of reviewers extracted the relevant data from the included studies using a data extraction template, and disagreements were resolved by consensus. We grouped the included studies into eight categories of model structure by examining their methodological approach based on definitions in Briggs et al. [16]. For each study, we extracted the following data.

- Study description: author, publication year, and country/setting.
- Policy/intervention details: intervention/policy evaluated, and target population.
- Model details: model name, model structure, and cost perspective.
- Study outcomes: health outcomes, cost outcomes, and currency year.

For each study, there was a particular focus on the model methodology and structure. We synthesised the extracted model characteristics to not only provide an overview of the included models but also to describe the modelled underlying risk factor to disease pathway, the effect of interventions on the model pathway to disease, and the approaches used to calculate health and economic outcomes.

Results

Search results

The search yielded a total of 1,958 articles after duplicates were removed. Only 230 full-text articles potentially met the eligibility criteria after title and abstract screening. After full-text assessment of the 230 articles against the inclusion criteria, 148 additional articles

were removed, leaving a total of 82 health economic modelling studies which were included in the review. Figure 1 presents a PRISMA flow chart describing the selection process. Table 1 presents a summary of the included health economic models and their study characteristics.

Study characteristics

The oldest published study included in the review was published in 1995 [47]. Out of the 82 included studies, only 9% were published between 1995 and 2008. There was an increase in the number of health economic modelling studies published in subsequent years, which has been sustained (Fig. 2). Policies were evaluated in a total of 64 countries globally (Fig. 3), and 66% of all included studies were conducted in high-income countries. Some of these studies conducted evaluations across multiple countries [99] or over specified epidemiological regions [46].

Policy interventions aimed at reducing dietary salt intake, alcohol consumption, or both were most frequently evaluated in the UK and Australia, with 23% and 18% of the studies focusing on these populations, respectively. Among all the included studies, countries in the European region were the most represented, while countries in Sub-Saharan Africa, the Eastern Mediterranean and Southeast Asia were the least represented (Fig. 3). Health economic modelling studies in low- or middle-income countries (LMICs) accounted for only 10% of the included studies.

Modelled population, interventions and risk factors

The modelled population in the included studies were mostly adults, generally ranging in age from 25 to 85 years. Several alcohol policy models specifically targeted at-risk groups, such as risky drinkers or individuals at high cardiovascular risk, within their evaluation [36, 41, 45]. Two alcohol modelling studies [24, 26] modelled HIV-infected persons and other at-risk populations, although there were no added considerations regarding the intervention effect on the target population. Only one study modelled a population of children aged 0–17 years, assessing the impact of dietary policies on their health over the course of their lives [58].

Most of the modelling studies evaluated at least one policy intervention to reduce salt intake or improve diet (58%), while 38% of the models were specifically developed to evaluate alcohol consumption policies. Only 4% of the included modelling studies evaluated both alcohol and salt-related policies.

The evaluated salt policies included sodium reformulations, sodium taxes, and nutrient labelling (Fig. 4). Sodium reformulation was the most common




Fig. 1 PRISMA-ScR flowchart outlining the inclusion and exclusion of the identified studies

intervention evaluated ($n=23$). The effect of these salt-reduction interventions is usually linked to health outcomes through systolic blood pressure and other risk reductions. For example, Wilson et al. [72] determined the risk of coronary heart disease (CHD) and stroke events based on the reduction in systolic blood pressure caused by the evaluated health intervention. Rubinstein et al. [92] also modelled the impact of health promotion campaigns through mass media on reducing salt consumption, focusing on both blood pressure and total cholesterol levels as intermediate risk factors for adverse health outcomes.

On the other hand, alcohol policies such as taxation and minimum unit pricing policies and primary care interventions were the most common interventions evaluated among the alcohol policy modelling studies (Fig. 4). Alcohol consumption frequency was the most common risk factor modelled in these studies, but there was no

modelled disease risk pathway through systolic blood pressure from alcohol to health outcomes. The effect of alcohol consumption on the risk of CVD, stroke events, and other alcohol-attributable diseases and complications was modelled directly. These intervention effect sizes are normally derived from observational studies or meta-analyses and are implemented on the target population over a predetermined time horizon.

The review identified only three (4%) studies that modelled both salt and alcohol as independent risk factors for disease in their economic evaluation [96–98]. These studies individually constructed a health economic decision model to evaluate multiple interventions to combat NCDs, including salt-reduction and alcohol taxation policies. Policies that target both salt and alcohol consumption and other risk factors include taxation policies and health promotion interventions. Other risk factors

Table 1 Summary of the included health economic models

Study Author (Year), Setting	Population	Policy details	Model name	Method/Structure	Health outcomes	Cost outcomes (perspective)
Alcohol policy models						
Brennan et al. (2022), United Kingdom [17]	adults aged 18+	national level minimum unit price policies for alcohol	Sheffield Alcohol Policy Model (Local Authority version 4.0)	comparative risk assessment, lifetable	hospitalisations, crimes and alcohol-attributable deaths and inequalities	NHS costs (healthcare)
Gibbs et al. (2022), South Africa [18]	drinking population aged 15 and older	minimum unit pricing of alcohol	epidemiological policy appraisal model	comparative risk assessment, multistate lifetable	alcohol consumption and expenditures, reduction in cases of catastrophic health expenditures, alcohol-related diseases averted	government healthcare cost savings, household savings linked to workplace absence (healthcare)
Brennan et al. (2021), United Kingdom [19]	population aged 18 years and over	minimum unit pricing of alcohol	Sheffield Alcohol Policy Model (version 4.0)	comparative risk assessment, multistate lifetable	alcohol-attributable deaths, hospitalisations and crime, QALYs	changes in alcohol-attributable NHS costs (healthcare)
Robinson et al. (2020), Australia [20]	population aged 15 years and over	uniform volumetric tax and minimum unit floor price on alcohol	ACE-Obesity Policy Model	multistate lifetable model	Health-adjusted life years	healthcare cost savings (societal)
Jiang et al. (2019), Australia [21]	population aged 16 and over	alcohol pricing policies: tax policy, minimum unit pricing	economic and epidemiological modelling	comparative risk assessment	deaths, DALYs	healthcare costs (healthcare)
Cobiac et al. (2019), New Zealand [22]	general population	increase in alcohol excise taxes	multistate life-table model	multistate lifetable model	QALYs	healthcare costs (healthcare)
Angus et al. (2017), 28 EU member states [23]	general population	national screening and brief interventions programme	meta-modelling approach based on SAPM (Sheffield Alcohol Policy Model)	comparative risk assessment, lifetable	QALYs gained, ICERs	Cost of GP, hospitalisation, net programme cost (healthcare)
Galarraga et al. (2017), Kenya [24]	HIV + persons	task-shifted cognitive-behavioural therapy	Generic	Cohort model	productivity improvements	training and administering task-shifted CBT therapy costs, averted cost from reduced likelihood of HIV transmission (societal)
Zur et al. (2016), Canada [25]	population aged 17 years and older	alcohol screening and brief intervention	microsimulation model of alcohol consumption	microsimulation	life years gained, QALYs gained	direct healthcare costs (healthcare)
Kessler et al. (2015), East Africa [26]	HIV infected persons	cognitive based treatment aimed at reducing hazardous alcohol consumption	computer simulation model	system dynamics model	Welfare-Adjusted Life Years	healthcare costs (healthcare)
Angus et al. (2014), Italy [27]	general population (16+)	Screening and brief interventions	Sheffield Alcohol Policy Model	comparative risk assessment, lifetable	QALY gains	Programme delivery cost and healthcare savings (healthcare)

Table 1 (continued)

Study Author (Year), Setting	Population	Policy details	Model name	Method/Structure	Health outcomes	Cost outcomes (perspective)
Brennan et al. (2014), United Kingdom [28]	Adults and young people aged 16 or more, including subgroups of moderate, hazardous, and harmful drinkers	minimum unit pricing	Sheffield Alcohol Policy Model (version 2.5)	comparative risk assessment, lifetable	Changes in mean consumption in terms of units of alcohol, drinkers' expenditure, and reductions in deaths, illnesses, admissions to hospital, and quality adjusted life years	healthcare costs (healthcare)
Holm et al. (2014), Denmark [29]	adult population aged 16 years or older	30% increased taxation, increased minimum legal drinking age, advertisement bans, limited hours of retail sales, and brief and longer individual interventions	Assessing Cost-Effectiveness in Prevention (ACE-Prevention) model	multistate lifetable model	DALYs averted	inpatient and outpatient costs (healthcare)
Holm et al. (2014), Denmark [30]	adult Danish population aged 16 years and older	changes in alcohol taxation	multistate lifetable model	multistate lifetable model	DALYs	intervention costs (healthcare)
Ditsuwan et al. (2013), Thailand [31]		Random breath testing, selective breath testing, and mass media campaigns	Generalized cost-effectiveness analysis	comparative risk assessment	DALYs averted	intervention costs, treatment cost savings (healthcare)
Purhouse et al. (2013), United Kingdom [32]	population aged 16 years and over	universal alcohol screening and brief intervention programmes in primary care	Sheffield Alcohol Policy Model	comparative risk assessment, lifetable	QALYs	screening costs, programme costs, alcohol-related costs, and NHS costs (healthcare)
Doran et al. (2013), Australia [33]	general population	volumetric tax; equal tax rate to all beverages equivalent to a 10% increase in the current excise applicable to spirits and ready-to-drink products; excise tax rate that increases exponentially by 3% for every 1% increase in alcohol content above 3.2%; and applying a two-tiered volumetric tax	ACE (Assessing the Cost Effectiveness)-Alcohol model	multistate lifetable model	DALYs	healthcare costs averted, taxation revenue (healthcare)
Popova et al. (2012), Canada [34]	general population	privatisation of alcohol sales, compared with government alcohol retailing systems	simulation model	comparative risk assessment	number of deaths, potential years of life lost	direct healthcare costs, indirect costs (productivity losses), direct costs of criminality (societal)

Table 1 (continued)

Study Author (Year), Setting	Population	Policy details	Model name	Method/Structure	Health outcomes	Cost outcomes (perspective)
Magnus et al. (2012), Australia [35]	2008 adult cohort aged 15–65 years	realistic target reduction in per capita annual adult alcohol consumption	population simulation model		DALYs	health sector costs, production gains or losses (societal)
Navarro et al. (2011), Australia [36]	Risky drinkers in 10 rural communities in New South Wales, Australia	GP-delivered interventions for alcohol misuse: screening, brief interventions, combination	decision model	decision tree	reduction in alcohol consumption	training and GP costs (healthcare)
Cadilhac et al. (2011), Australia [37]	adult population aged 15 and over	feasible reduction in behavioural risk factors (alcohol)	population simulation model		DALYs, avoidable disease, deaths	health sector costs (societal)
Purshouse et al. (2010), United Kingdom [38]	adults aged 18 years or over	alcohol pricing policies	Sheffield Alcohol Policy Model version 1.1	comparative risk assessment, lifetable	QALYs	healthcare costs (healthcare)
Barbosa et al. (2010), United Kingdom [39]	all males	Motivational enhancement therapy, compared with social behaviour and network therapy	probabilistic lifetime Markov model	Markov model	years of life, QALYs	lifetime treatment costs and disease-related costs (healthcare)
Byrnes et al. (2010), Australia [40]	general population	volumetric alcohol taxation	multistate lifetable model	multistate lifetable model	DALYs averted	cost to government, cost savings, intervention cost (healthcare)
Tariq et al. (2009), the Netherlands [41]	Risky drinkers aged between 20 and 65 who visit the GP yearly	Screening and brief interventions	RIVM Chronic Disease Model	Markov model	QALYs gained	intervention and healthcare costs (healthcare)
Cobiac et al. (2009), Australia [42]	population aged 18 years and over	volumetric taxation, advertising bans, an increase in minimum legal drinking age, licensing controls on operating hours, brief intervention (with and without general practitioner telemarketing and support), drink driving campaigns, random breath testing	multi-state, multiple cohort lifetable approach	multistate lifetable model	DALYs averted	healthcare costs (healthcare)
Van den Berg et al. (2008), the Netherlands and Sweden [43]	entire population	alcohol tax increases	RIVM Chronic Disease Model	Markov model	QALYs gained	healthcare costs (healthcare)

Table 1 (continued)

Study Author (Year), Setting	Population	Policy details	Model name	Method/Structure	Health outcomes	Cost outcomes (perspective)
Lai et al. (2007), Estonia [44]	general population	excise tax on alcoholic beverages; reduced access to alcoholic beverage retail outlets; a comprehensive advertising ban (TV, radio and billboards) on alcoholic products; roadside breath-testing for blood alcohol content in motor vehicle driver; and brief interventions involving counselling to at-risk drinkers by a primary care physician	WHO-CHOICE	comparative risk assessment	DALYs	patient and programme costs (societal)
Mortimer et al. (2005), Australia [45]	heavy drinkers aged 19 and over	brief interventions for problem drinking	Time-dependent state-transition model	Markov model	Health-related quality of life (HRQoL) gain	(societal)
Chisholm et al. (2004), 12 epidemiological WHO subregions [46]	Individuals at risk of alcohol use	Interventions to reduce use of alcohol and tobacco use	population model		cost per DALYs averted	(healthcare)
Downs et al. (1995), United States of America [47]	Adolescents aged 15 to 19 years	screening visits for all adolescents and counselling visits for youth identified as high risk	cost-effectiveness model	decision tree	cost-effectiveness	direct and intervention costs (societal)
Salt policy models						
Aminde et al. (2023), Australia [48]	Adult population	Achieving the Australian national sodium reduction targets	proportional multistate lifetable model	multistate lifetable Markov model	Chronic kidney disease incidence, disease deaths, HALYs, life expectancy	Annual health spending for chronic kidney disease (healthcare)
Ikeda et al. (2022), Japan [49]	adults aged 40 to 79 years	achieving global and national salt-reduction targets (8, < 6, and < 5 g/day)	discrete-time Markov cohort macro-simulation model	Markov model	disease incidence	outpatient care and drug prescription costs (healthcare)
Thomas et al. (2022), United Kingdom [50]	adults aged 16 and over	advertising restrictions on high fat, salt and sugar products	School for Public Health Research (SPHR) diabetes prevention model (version 4)	microsimulation	QALYs, new type 2 diabetes cases, cardiovascular disease events	lifetime healthcare costs (healthcare)
Bates et al. (2022), United Kingdom [51]	individuals with, or without diabetes	behavioural weight loss maintenance	SPHR diabetes prevention model	microsimulation	QALYs	healthcare cost (healthcare)
Nilson et al. (2021), Brazil [52]	adults aged 30 to 79 years	voluntary sodium reduction targets	IMPACT(NCD-Brazil)	microsimulation	cardiovascular disease cases and deaths prevented or postponed	formal and informal healthcare costs (healthcare)

Table 1 (continued)

Study Author (Year), Setting	Population	Policy details	Model name	Method/Structure	Health outcomes	Cost outcomes (perspective)
Alonso et al. (2021), United Kingdom [53]	adult population	national and international (WHO) population-level salt intake targets	PRIMEtime-CE Model	multistate lifetable	CVD-related cases averted, life years gained, and QALYs gained	healthcare and social care savings (healthcare)
Aminde et al. (2021), Vietnam [54]	Adults aged 25 and over	Population reduction in salt intake to national and WHO targets	proportional multistate lifetable model	multistate lifetable model, Markov	changes in blood pressure, stroke incidence, deaths, HALYs	healthcare costs (healthcare)
Nilson et al. (2020), Brazil [55]	adult population	population-wide reduction of salt consumption to 5 g/day	Preventable Risk Integrated Model (PRIME)	comparative risk assessment	deaths prevented	direct healthcare cost: inpatient care, outpatient care, and medications (healthcare)
Breeze et al. (2020), United Kingdom [56]	HbA1c 6–6.4%, aged 16, no existing diabetes diagnosis	NHS diabetes prevention programme	SPHR diabetes prevention model	microsimulation	QALYs gained	lifetime cost savings of the NHS diabetes prevention programme (healthcare)
Aminde et al. (2020), Cameroon [57]	adult population (30 years and above)	population salt reduction strategies: mass media campaign, school education programme, low sodium salt substitute	proportional multistate lifetable model	multistate lifetable Markov model	disease incidence, mortality, HALYs	healthcare costs (healthcare)
Mytton et al. (2020), United Kingdom [58]	children aged 0–17 years	HFSS television advertising restrictions between 05.30 h and 21.00 h	PRIMEtime multi-state lifetable model	multistate lifetable model	DALYs	healthcare costs, social care costs, employment costs, health-related net monetary benefits (societal)
Blakely et al. (2020), New Zealand [59]	general population	salt tax	proportional multistate lifetable model	multistate lifetable model	HALYs	health expenditure (healthcare)
Laverty et al. (2019), United Kingdom [60]	adult population	Public Health Responsibility Deal	IMPACT(NCD) model	microsimulation	CVD and gastric cancer cases and deaths	healthcare costs and workplace productivity losses (societal)
Collins et al. (2019), United States of America [61]	adults aged 30 to 84 years	achieving FDA reformulation targets for sodium	US IMPACT Food Policy Model	microsimulation	QALYs gained	health care costs, productivity, informal care, and industry and governmental costs of reformulation (societal)
Briggs et al. (2019), United Kingdom [62]	general population	Salt reformulation	PRIMEtime CE model	multistate lifetable model	QALYs	NHS savings, social care savings, intervention costs (societal / economic)
Kypridimos et al. (2018), United Kingdom [63]	adults aged 30 to 84 years	NHS Health Check programme with additional interventions including mandatory salt reformulation of processed foods	IMPACT(NCD) model	microsimulation	disease cases and deaths prevented or postponed, QALYs gained	programme costs (healthcare and societal)

Table 1 (continued)

Study Author (Year), Setting	Population	Policy details	Model name	Method/Structure	Health outcomes	Cost outcomes (perspective)
Basu et al. (2018), the Middle East [64]	Palestinian refugees	alternative food parcels, compared to usual food parcels	microsimulation model	microsimulation	type-2 diabetes, and cardiovascular disease morbidity and mortality, DALYs	healthcare expenditures (healthcare and societal)
Pearson-Stuttard et al. (2018), United States of America [65]	adults aged 30 to 84 years	voluntary sodium reduction	US IMPACT Food Policy Model	microsimulation	CVD deaths and cases prevented or postponed, QALYs, life years gained	medical costs and policy costs (healthcare and societal)
Brown et al. (2018), Australia [66]	general population	legislation to restrict high in fat, sugar and salt (HFSS) TV advertising	proportional multi-state lifetable model	multistate lifetable model	HALYs	healthcare cost savings (societal)
Li et al. (2017), China [67]	families (elderlies aged 65+) with 10-year-old children	school-based education program to reduce salt intake	5-state Markov model	Markov model	QALYs, deaths averted	intervention cost, medical costs (healthcare)
Cobiac et al. (2017), Australia [68]	general population	taxing excess salt in processed foods	proportional multistate lifetable model	multistate lifetable model	DALYs averted	healthcare costs (healthcare)
Webb et al. (2017), global: 183 countries [69]	general population	10% reduction in sodium consumption	comparative risk assessment model	comparative risk assessment	DALYs	intervention costs (healthcare)
Wang et al. (2016), China [70]	adult population aged 35–94 years	national dietary salt reduction goals	CVD Policy Model	Markov model	QALYs; CVD incidence and mortality	health care costs, acute treatment costs, and chronic state costs of CVD (healthcare)
Watkins et al. (2016), South Africa [71]	general population	salt reduction policy	Extended Cost-Effectiveness Analysis salt reduction model	Markov model	cases of catastrophic health expenditure averted, cases of poverty averted, cardiovascular disease cases averted	average out-of-pocket cost of CVD care, treatment costs (societal)

Table 1 (continued)

Study Author (Year), Setting	Population	Policy details	Model name	Method/Structure	Health outcomes	Cost outcomes (perspective)
Wilson et al. (2016), New Zealand [72]	adults aged 35 years and over	ten interventions to achieve WHO sodium reduction targets: full target achieved via packaged food target, fast food target and reduced discretionary use; Packaged foods target achieved; Fast food and restaurant target achieved; Bread target achieved; Processed meats target achieved; Sauces target achieved; Snack food target achieved; Cheese target achieved; combination package; all bread and bakery target achieved	Markov macro-simulation model	Markov model	incidence, prevalence and case-fatality rates of CHD and stroke, QALYs	health system costs (health-care)
Nghiem et al. (2016), New Zealand [73]	population aged 35 years and over	Mandatory sodium substitution in processed foods, and limits on sodium in bread	Markov macro-simulation model	Markov model	QALYs	net health system costs (healthcare)
Wilcox et al. (2015), Syria [74]	adults aged 25 to 84 years	health promotion campaign, labelling of salt content on packaged foods, mandatory reformulation, and combinations	IMPACT CHD model in Syria	comparative risk assessment	life years gained	total policy cost minus healthcare savings (healthcare)
Nghiem et al. (2015), New Zealand [75]	population aged 35 years and over	Counselling, Endorsement label programme, mandatory sodium reduction and reformulation, Mass media campaign, salt tax, Sinking Lid	Markov macro-simulation model	Markov model	QALY, cardiovascular disease mortality rate	health system cost (health-care)
Mason et al. (2014), Tunisia, Syria, Palestine, Turkey [76]	general population	health promotion campaign, labelling of food packaging, mandatory salt reduction of processed foods (reformulation)	IMPACT CHD model	comparative risk assessment	life years gained, deaths prevented or postponed	cost saved in private sector, public sector, health care (societal)
Collins et al. (2014), United Kingdom [77]	adults aged 25 years and over	Change4Life, Labelling, Mandatory and voluntary reformulation	IMPACT CHD model	comparative risk assessment	life years gained	health care costs, policy and monitoring costs (healthcare)

Table 1 (continued)

Study Author (Year), Setting	Population	Policy details	Model name	Method/Structure	Health outcomes	Cost outcomes (perspective)
Ortegon et al. (2012), sub-Saharan Africa and South East Asia [78]	general population	Voluntary or regulatory reduction in dietary salt intake (amongst 123 single or combined prevention and treatment strategies for CVD, diabetes and smoking)	WHO-CHOICE model, including PopMod	comparative risk assessment, multistate lifetable model	DALYs averted	patient and programme costs (healthcare)
Ferrante et al. (2012), Argentina [79]	adult population over the age of 35 to 84	reducing salt content in food by 5–25%	Coronary Heart Disease Policy Model	Markov model	QALY gains	cost of intervention and heart disease (healthcare)
Cobiac et al. (2012), Australia [80]	Australian men and women, aged 35 to 84 years, who have never experienced a CVD event (angina, myocardial infarction, or stroke)	One salt intervention amongst 9 targeting CVD —mandatory reduction of salt in manufacture of breads, margarines and cereals.	discrete time Markov model	Markov model	health gain (DALYs)	intervention costs (healthcare)
Dodhia et al. (2012), United Kingdom [81]	population aged 16 and over	salt reduction in the population, dietary approaches to stop hypertension	Excel spreadsheet simulation model	Markov model	DALYs, YLLs, YLDs, deaths and avoidable deaths	intervention, medical and pharmacological costs (healthcare)
Barton et al. (2011), United Kingdom [82]	Entire population	legislation to reduce salt intake and ban industrial fats	Spreadsheet model	comparative risk assessment	Cardiovascular events avoided, QALYs gained	savings in healthcare costs (healthcare)
Ha et al. (2011), Vietnam [83]	general population	Health education through mass media education to reduce salt intake, and voluntary reduction in salt content of processed foods	WHO-CHOICE, including PopMod	comparative risk assessment, multistate lifetable	DALYs averted	programme and patient-related costs (societal)
Martikainen et al. (2011), Finland [84]	Population aged 30–74 years	reduced daily salt intake and replacement of saturated fat with polyunsaturated fat	state transition Markov cohort model	Markov model	QALYs	direct cost of prevention, morbidity, rehabilitation and production losses due to non-fatal CVD events (societal)
Rubinstein et al. (2010), Argentina [85]	Argentinian population over 35 years old	Voluntary salt reduction in breads	population-level comparative risk assessment	comparative risk assessment	DALYs	intervention costs (healthcare)
Smith-Spangler et al. (2010), United States of America [86]	US adults aged 40–85 years	sodium tax and voluntary sodium reduction in processed foods	computer-simulated, state-transition Markov cohort model	Markov model	QALYs, life years gained, CVD events averted	total savings in medical costs, incremental costs (societal)

Table 1 (continued)

Study Author (Year), Setting	Population	Policy details	Model name	Method/Structure	Health outcomes	Cost outcomes (perspective)
Bibbins-Domingo et al. (2010), United States of America [87]	general population	national effort to reduce salt consumption by 3 g per day	Coronary Heart Disease (CHD) Policy Model	Markov model	incidence of CHD, stroke, myocardial infarctions, and deaths from any related cause, QALYs	healthcare savings (healthcare)
Cobiac et al. (2010), Australia [88]	Population aged 30–100 years	dietary advice for everyone or high-risk individuals; incentivised (voluntary) and mandatory moderate salt limits in processed foods	proportional multistate lifetable model	multistate lifetable model	DALYs averted	healthcare and intervention costs (healthcare)
Palar et al. (2009), United States of America [89]	adults aged 18 or older	reduction of population-level dietary sodium consumption	cross-sectional simulation model	comparative risk assessment	QALYs, hypertension prevalence	direct healthcare cost savings (healthcare)
Dall et al. (2009), United States of America [90]	adult population	population-wide sodium intake reduction	Nutrition Impact Model	comparative risk assessment	cases of hypertension	medical cost savings (healthcare)
Akkazieva et al. (2009), Kyrgyzstan [91]	general population	Health education through mass media to reduce daily salt intake	WHO-CHOICE model	comparative risk assessment	DALYs averted	Intervention cost (healthcare)
Rubinstein et al. (2009), Argentina [92]	Population of Buenos Aires	health education through mass media to reduce salt consumption, and voluntary reduction of salt in bread	WHO-CHOICE methodology, and a standard multi-state modelling tool, PopMod	comparative risk assessment, multistate lifetable model	DALYs saved	hospital admission costs, intervention cost, and yearly treatment cost, (government/public sector)
Asaria et al. (2007), 23 countries, including low-income and middle-income countries (Russia, Ukraine, Poland, Turkey, Burma, Indonesia, Egypt, Vietnam, India, South Africa, China, Philippines, Iran, Argentina, Brazil, Bangladesh, Pakistan, Thailand, Colombia, Nigeria, Mexico, DR Congo, Ethiopia) [93]		voluntary reduction in salt content of processed foods, and mass media campaign	WHO Comparative Risk Assessment	comparative risk assessment	deaths averted, cardiovascular mortality	healthcare and intervention costs (healthcare)
Murray et al. (2003), South East Asia, Latin America and Europe [94]	high cardiovascular risk individuals	Salt reduction through voluntary agreements with industry and population-wide reduction in salt intake legislation	PopMod (WHO-CHOICE)	multistate lifetable model	cost per DALYs averted	programme and patient-level costs (healthcare)

Table 1 (continued)

Study Author (Year), Setting	Population	Policy details	Model name	Method/Structure	Health outcomes	Cost outcomes (perspective)
Selmer et al. (2000), Norway [95]	1995 Norwegian population aged 40 and over	Health promotion; reformulation, labelling; taxes on salty food/subsidies of products with less salt	dynamic simulation model	Markov model	life years gained	avoided healthcare costs, increased productivity, avoided time loss, cost of health care in extended life, intervention cost, welfare losses (societal)
Joint alcohol and salt policy models						
Bertram et al. (2021), Eastern sub-Saharan Africa and South East Asia [96]	general population	77 interventions for prevention and control of NCDs and MNS (mental, neurological and substance use disorders) including taxation, voluntary and legislative actions to reduce sodium intake	WHO CHOICE	comparative risk assessment, multistate lifetable	Healthy Life Years	patient level delivery costs, programmatic costs and health system costs (healthcare)
Cheatley et al. (2021), 36 countries (South Africa, Japan, Australia, Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Iceland, Italy, Lithuania, Latvia, Malta, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slovak Republic, Slovenia, Spain, Sweden, Switzerland, United Kingdom, Canada, Mexico) [97]	general population	food menu labelling, mass media campaigns, alcohol tax, minimum unit pricing	OECD Strategic Public Health Planning for NCDs (SPHeP-NCDs) model	microsimulation	cancer-related health outcomes (incidence and mortality), DALYs	healthcare costs (healthcare)
Salomon et al. (2012), Mexico [98]	general population	voluntary industry salt reduction and legislation to reduce salt in processed foods; alcohol taxation, reduced access, comprehensive advertising ban, brief advice in primary healthcare	multistate population model PopMod	multistate lifetable model	DALYs	patient, programme and training costs (societal)




Fig. 2 Publication years of included modelling studies

Studies




Fig. 3 Map showing number of alcohol and salt modelling studies globally

for NCDs that were included in these models included smoking and cholesterol concentration.

Multiple risk factors were therefore incorporated in the health economic models included in this review,

including total blood cholesterol levels, body mass index (BMI), type 2 diabetes status, overweight/obese status, drinking history, hypertensive status, and history of other cardiovascular diseases. These risk factors were either




Fig. 4 Number of studies evaluating eight categories of salt and alcohol policies examined in the review

assumed to be associated with salt or alcohol consumption or independent of them in relation to the modelled outcomes and diseases.

Model outcome measures and diseases

Of the 82 included studies, 59 (72%) assumed a healthcare system perspective in the costing approach used in their economic evaluation, while 23 (28%) evaluated from the societal perspective. The healthcare system perspective was defined as a costing perspective amalgamating the healthcare system, government, public sector, and financial cost perspectives. The majority of these studies included direct healthcare, intervention/programme implementation, and informal care costs in their economic analyses. The additional cost components considered from the societal perspective include other economic costs such as productivity gains or losses, health-related net monetary benefits, and avoided time loss. These costs were obtained from publications or estimated by local experts.

Reported health outcomes from economic evaluations include health-adjusted life-year metrics such as quality-adjusted life years (QALYs) gained and disability-adjusted life years (DALYs) averted. Studies also reported epidemiological estimates such as deaths prevented or

postponed, disease cases averted, incidence and morbidity (Table 1).

The studies differed in the range of complications and comorbidities considered as outcomes. The range of diseases modelled across the included studies covered the main diet-related cardiometabolic outcomes, cancers, and alcohol-attributable harm (Table 2). The most common diseases reported were cardiovascular diseases (79%), cerebrovascular complications (66%), and cancers (35%), as well as various complications and harms attributable to alcohol (44%) (Fig. 5).

Among the diseases included in both the salt and alcohol policy models, CHD was the most common modelled cardiovascular disease. The IMPACT CHD model evaluated salt-reduction policies in the UK and Syria populations [74, 76, 77]. The expected change in population salt intake from the interventions was translated into a change in mean blood pressure in the modelled populations. This policy effect was subsequently used to estimate the hypertension prevalence and coronary heart disease deaths prevented or postponed.

Hypertension was modelled explicitly as a health outcome in some of the included salt models; hence, the costs of medication and treatments were included [50, 61, 63, 64, 71]. Hypertension, or systolic blood pressure, was


Table 2 Adverse health outcomes included in modelling studies

Study	Cardiovascular diseases	Cerebrovascular diseases	Diabetes	Cancers	Digestive and liver diseases	Alcohol-related injuries/accidents	Alcohol-related complications
Gibbs et al. [18]				✓	✓	✓	
Robinson et al. [20]	✓	✓	✓	✓			
Cobiac et al. [22]						✓	
Jiang et al. [21]							✓
Galarraga et al. [24]							
Angus et al. [23]						✓	✓
Zur et al. [25]	✓	✓	✓	✓	✓	✓	
Kessler et al. [26]							
ACE-Prevention model [29, 30]	✓	✓		✓	✓		✓
Doran et al. [33]						✓	✓
Ditsuwan et al. [31]						✓	
Magnus et al. [35]							✓
Popova et al. [34]						✓	✓
Cadilhac et al. [37]	✓	✓		✓			
Navarro et al. [36]							✓
Byrnes et al. [40]	✓	✓		✓	✓		✓
Barbosa et al. [39]							✓
Sheffield Alcohol Policy Model [17, 19, 27, 28, 32, 38]	✓	✓	✓	✓	✓	✓	✓
Cobiac et al. [42]	✓	✓		✓	✓	✓	✓
RIVM Chronic Disease model [41, 43]	✓	✓		✓			
Lai et al. [44]	✓			✓			
Mortimer et al. [45]							✓
Chisholm et al. [46]	✓				✓		
Downs et al. [47]					✓		
Cheatley et al. [97]				✓			
Bertram et al. [96]	✓		✓				✓
Salomon et al. [98]	✓		✓	✓			✓
Aminde et al. [48]					✓		
Ikeda et al. [49]	✓	✓					
Aminde et al. [54]		✓					
Alonso et al. [53]	✓	✓					
Nilson et al. [52]	✓	✓					
Blakely et al. [59]	✓	✓	✓	✓			
Mytton et al. [58]	✓	✓	✓	✓			
Aminde et al. [57]	✓	✓					
SPHR Diabetes prevention model [50, 51, 56]	✓	✓	✓	✓			
Nilson et al. [55]	✓	✓					
Briggs et al. [62]	✓	✓	✓	✓	✓		
Laverty et al. [60]	✓			✓			
Brown et al. [66]	✓	✓	✓	✓			
US IMPACT Food Policy model [61, 65]	✓	✓					
Basu et al. [64]	✓		✓				
Kypridimos et al. [63]	✓	✓	✓				
Cobiac et al. [68]	✓	✓		✓			
Li et al. [67]	✓	✓					
Nghiem et al. [73]	✓	✓					

Table 2 (continued)

Study	Cardiovascular diseases	Cerebrovascular diseases	Diabetes	Cancers	Digestive and liver diseases	Alcohol-related injuries/accidents	Alcohol-related complications
Wilson et al. [72]	✓	✓					
Watkins et al. [71]	✓	✓					
Wang et al. [70]	✓	✓					
Webb et al. [69]	✓						
Nghiem et al. [75]	✓	✓					
IMPACT CHD model [74, 76, 77]	✓						
Dodhia et al. [81]	✓	✓					
Cobiac et al. [80]	✓	✓					
Ortegon et al. [78]	✓	✓	✓				
Martikainen et al. [84]	✓	✓					
Ha et al. [83]	✓	✓					
Barton et al. [82]	✓	✓					
Cobiac et al. [88]	✓	✓					
Coronary Heart Disease policy model [79, 87]	✓	✓					
Smith-Spangler et al. [86]	✓	✓					
Rubinstein et al. [85]	✓	✓					
Rubinstein et al. [92]	✓	✓					
Akkazieva et al. [91]	✓	✓					
Dall et al. [90]	✓	✓		✓	✓		
Palar et al. [89]	✓	✓					
Asaria et al. [93]	✓						
Murray et al. [94]	✓						
Selmer et al. [95]	✓	✓					

RIVM (the Dutch National Institute for Public Health and the Environment), SPHR (School for Public Health Research), ACE-Prevention (Assessing Cost-Effectiveness in Prevention) model

**Fig. 5** Modelled disease outcomes in included studies

an intermediate risk factor for CVD in 40 (83%) of the salt modelling studies but not in the alcohol policy models. Aminde et al. [54] reported changes in blood pressure

after a population reduction in salt intake to WHO targets using a proportional multistate lifetable model. The model then estimates the impact of blood pressure

changes on stroke incidence and mortality. This cerebrovascular event was therefore modelled downstream as a complication of high blood pressure and was not directly associated with excessive salt intake.

Other non-hypertensive complications included as explicit health outcomes in the health economic models include diabetes, liver cirrhosis, chronic kidney disease, and various cancers. Cancers which were modelled with salt as a risk factor included breast cancer (in women), gastric, kidney, liver, colorectal, kidney and bowel cancer. These cancers, as well as oesophageal, laryngeal, rectal and oropharyngeal cancer, were also attributable to alcohol consumption in some alcohol policy models. In addition, Brennan et al. [17] reported hospitalisations, crimes and alcohol-attributable deaths and inequalities that result from implementing an alcohol pricing policy, while Gibbs et al. [18] presented changes in alcohol consumption and expenditures when implementing such policies. These health economic outcomes were estimates of the burden of alcohol-related complications and injuries such as road traffic injuries, falls, fires, suffocation, and self-harm.

Modelling methodology and structures

The models varied widely, from individual-level and cohort state-transition models, to attributable fraction models using a comparative risk assessment method,

though none of the studies explored any interaction between individuals. The studies utilised the following epidemiological modelling methods: comparative risk assessments (29%), multistate lifetables (27%), Markov cohort (22%), microsimulation (13%), decision trees (3%), system dynamics models (1%), and other unspecified models (5%) (Fig. 6). There were no agent-based or discrete event simulation modelling studies included in this review. Some of these studies were based on established models that have been applied in different populations to evaluate different policies, with minimal changes in the model structure.

PopMod is one of the first published multistate dynamic lifetable modelling tools that has facilitated disease modelling and cost-effectiveness analysis for priority setting in diverse settings [100]. Murray et al. [94] used this tool to simulate the evolution of a stable population for the cost-effectiveness analysis of interventions to reduce cholesterol and systolic blood pressure in different areas of the world. The structure of this analysis was based on a system of ordinary differential equations that models the temporal evolution of a population subjected to two disease conditions.

Salomon et al. [98] also used the PopMod tool to estimate the cost-effectiveness of various interventions, including salt-reduction and alcohol interventions, to reduce the burden of non-communicable diseases in




Fig. 6 Percentage abundance of structures used in identified models

Mexico. This finding demonstrated the transferability of the model, which not only models interacting disease conditions but also incorporates both alcohol use and salt intake via systolic blood pressure as risk factors for disease. This modelling tool is typically used in the WHO-CHOICE programme [101, 102]. Moreover, comparative risk assessment (CRA) models have been used to estimate the cost-effectiveness of salt and alcohol interventions for combating NCDs in diverse settings in Southeast Asia, Eastern Sub-Saharan Africa, and a range of low- or middle-income countries (LMICs), making the results more comparable [93, 96].

The Dutch National Institute of Public Health and Environmental Protection (RIVM) Chronic Disease model was used to simulate the change in prevalence rates of diseases causally related to alcohol consumption caused by an intervention [41, 43]. The relative risks for diseases related to alcohol consumption were derived from a meta-analysis with estimates for different alcohol consumption categories. The Assessing Cost-Effectiveness (ACE) in Prevention model, developed in Australia, enables a comprehensive cost-effectiveness analysis of preventative intervention options [29, 33]. Over the years, both the ACE-prevention and RIVM models have undergone adaptations to incorporate updated inputs and accommodate changes to their structure [103].

The proportional multistate lifetable Markov model is a dynamic epidemiological model well suited for comparing multiple countries and providing valuable insights for the prioritisation of preventive interventions at the national, regional, and global levels [104]. It has been used to model preventive interventions with the aim of reducing both salt- and alcohol-attributable disease burden [42, 68, 88]. In this model, disease progression is estimated in Markov health states and linked to the multiple cohort lifetable.

This multistate lifetable approach was adopted in the UK for the PRIMETIME Cost-Effectiveness model, which estimates diet changes on morbidity and mortality via blood pressure, cholesterol and body weight [105]. This model facilitated the evaluation of the 2003 to 2018 population salt reduction program implemented in England, with the model projecting its impact by 2050 [53]. The downstream effect of salt intake on systolic blood pressure was modelled, which then estimated the risk of CVD burden and the healthcare and social care utilisation needed.

The IMPACT CHD model, developed in the UK, uses a population-attributable risk fraction approach to estimate the cost effectiveness of salt reduction policies for reducing coronary heart disease in England, Syria, and other Eastern Mediterranean countries [74, 76, 77]. This CRA methodology is commonly applied for alcohol models such as the Sheffield Alcohol Policy Model

[106], which also incorporates lifetables in its structure to estimate the effect of alcohol pricing policies such as the minimum unit pricing policy [28, 38]. This model applies the potential impact fraction framework to estimate the impact of changes in alcohol consumption on various alcohol-related harm.

Microsimulation models are becoming increasingly common in the health economics field since they address the limitation of cohort models in capturing the variation in individual characteristics [107]. The School for Public Health Research diabetes prevention model uses this methodology in the evaluation of dietary, lifestyle, and diabetes interventions [50, 51, 56]. The modelled effect of restricting advertising for foods high in fat, salt and sugar was on caloric intake and BMI, so the impact of salt intake on blood pressure was not considered [50]. However, the individual patient model structure allowed heterogeneity in the estimation of HbA1c, systolic blood pressure, cholesterol and BMI as risk factors for disease.

The OECD's Strategic Public Health Planning Model for Non-communicable Diseases also uses a microsimulation approach to estimate the economic impact of primary prevention policies, such as food menu labelling and alcohol taxes [97]. This microsimulation model addresses all major threats related to non-communicable diseases, such as diabetes, cancer, and cardiovascular diseases, as well as injuries and mental health issues. Additionally, it considers modifiable risk factors such as harmful alcohol consumption, unhealthy diet, physical inactivity, and tobacco use. The country-level risk factor profiles and disease epidemiology data are input into an annual microsimulation to generate outputs on health outcomes, healthcare expenditures, and labour force expenditures.

Discussion

This study aimed to determine the scope of the published literature and review existing evidence on the modelling methods and structures used in health economic models evaluating salt- and/or alcohol-reduction public health policies. These findings indicate growing interest in using health economic models to evaluate the health and economic impacts of interventions targeting salt or alcohol consumption. The increase in studies since the 2010s is likely linked to the development of key health economic models, such as the ACE-prevention and Sheffield Alcohol Policy models, which have either been adapted or inspired similar models for evaluating health policies. The study also highlights the increasing role of health economic models in evidence-based policymaking, especially in high-income countries.

This review gains value from encompassing studies conducted across low-, middle-, and high-income

countries. It highlights the lack of health economic modelling studies in LMICs, where the burden of non-communicable diseases, driven in part by alcohol and salt consumption, is increasing [1]. As a result, the use of health economic modelling tools and evidence to support health priority setting in these countries may be limited. Dotsch-Klerk et al. [8] suggested that the limited availability of data, such as epidemiological data and cost data, in lower income countries may explain the limited number of modelling studies from those countries. This is of concern because generating the cost-effectiveness evidence of primary prevention strategies, which is critical in settings with limited financial resources, could be crucial for reducing the burden of NCDs.

The World Health Organisation Choosing Interventions that are Cost-Effective (WHO-CHOICE) programme has been instrumental in such cost-effectiveness analyses of health interventions globally [108]. The use of standardised methods across disease areas is a major added value of the CHOICE approach, as it allows for fair comparisons between and across health programmes. The WHO-CHOICE has developed a software tool, the OneHealth tool (<https://www.who.int/tools/onehealth>), to help analysts and decision-makers conduct country-based and regional cost-effectiveness analyses of various health interventions for strategic planning and costing. This tool will enable the use of health economic modelling in LMICs to assess the cost-effectiveness of different health strategies for priority setting and resource allocation.

There is also potential for developing joint dietary salt and alcohol policy models that evaluate public health policies targeting both risk factors, exploring their association or integrated effects on health and economic outcomes. Such analyses would require input data (or assumptions) on the joint effects of salt and alcohol consumption, potentially derived from observational studies, clinical models or RCTs. These models could support policymaking aimed at reducing disease burden and assist in priority setting, particularly in resource-constrained settings. For example, health-related food taxes could be evaluated across different dietary behaviour targets, helping decision-makers compare cost-effectiveness across various policies.

The strength of this review lies in its potential to inform the development of public health economic models for evaluating alcohol and salt reduction strategies. By identifying and examining common modelling pathways and approaches, it provides a foundation for adapting these methods for future models. This review explores the effects of alcohol and dietary salt reduction interventions on health outcomes, both directly and through intermediate risk factors such as systolic blood pressure,

summarising the various modelling pathways used. While a detailed review of the epidemiological studies estimating the effects of these intermediate risk factors on health outcomes would be valuable, it was beyond the scope of this review.

Previous systematic reviews of salt or alcohol models have provided an overview and critically appraised economic models that have served their purpose in informing policymakers about the availability of modelling techniques [6]. However, to our knowledge, no studies have compared the differing modelling structures of alcohol and salt models, or explored their risk factor pathways to disease. Furthermore, the systematic approach used for the literature search and data collection ensures rigour.

A limitation of this review is that it did not assess the quality of the identified economic evaluations, nor did it include a critical analysis of the models in regard to the appropriateness of modelling methods in health economic studies, as this was not the intended purpose of the review. The purpose of this scoping review was to provide an overview of the health economic models and the methods used. Therefore, a systemic evaluation of the included studies and a risk of bias assessment were not needed. Another limitation is that only studies published in English were included, which means that methods used by other studies published in other languages might have been missed.

Nonetheless, the review findings can inform economic evaluation methods for analysing the cost-effectiveness of salt and alcohol public health policies. The evidence base generated from health economic models can underpin policymaking on alcohol and salt reduction in the population. Future research should prioritise the development of health economics models that incorporate multiple risk factors of disease and are broadly applicable for evaluating related interventions. Such models would enable cost-effectiveness analyses of policies targeting multiple risk factors, such as alcohol and salt, to support priority setting.

Conclusions

This scoping review identified modelling studies used to evaluate policies and lifestyle interventions to reduce salt and/or alcohol intake. It offers valuable insights into the diverse public health economic modelling approaches, highlighting their varying complexities and information requirements in estimating the health and economic impacts of these interventions. This review revealed that systolic blood pressure was a key intermediate risk factor in the excessive salt-to-disease modelling pathway for most studies. However, the effects of alcohol consumption on adverse health effects are

usually modelled directly using estimates of the relative risk of disease. We identified only a few modelling studies that incorporate both alcohol and salt as risk factors. It is also clear from this review that incorporating multiple risk factors in health economic model evaluations, especially in LMICs where it's limited, will generate the needed cost-effectiveness evidence for decision makers, to facilitate the implementation of policies to reduce both salt and alcohol consumption.

Abbreviations

ACE	Assessing Cost-Effectiveness
BMI	Body mass index
CHD	Coronary heart disease
CRA	Comparative risk assessment
CVD	Cardiovascular disease
DALY	Disability-adjusted life year
DES	Discrete event simulation
LMIC	Low- or middle-income country
NCD	Non-communicable disease
QALY	Quality-adjusted life year
RCT	Randomised controlled trial
RIVM	National Institute for Public Health and the Environment
WHO	World Health Organisation

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12889-024-21237-7>.

Supplementary Material 1.

Acknowledgements

We would like to thank Louise Falzon for refining the search strategy and James Oguta (JO) for contributing to the selection of papers against the inclusion and exclusion criteria.

Authors' contributions

JPM developed the scoping review protocol, searched the electronic databases, selected the papers by applying the inclusion and exclusion criteria, summarised the findings and interpreted the results, and drafted and had primary responsibility for the final content of the paper. AB, CT, and RA contributed to the design of the study, revised the review protocol, and contributed to the paper. All the authors read and approved the final manuscript.

Funding

This scoping review was funded by the University of Sheffield and the Wellcome Trust as part of a PhD studentship.

Data availability

All data generated or analysed during this study are included in this published article [and its supplementary information file].

Declarations

Ethics approval and consent to participate

A prior abstract from this review was previously published in *Value in Health* [109] as part of the ISPOR Europe 2023 conference held in Copenhagen, Denmark, from 12th November to 15th November 2023. This conference abstract can be found here: <https://doi.org/10.1016/j.jval.2023.09.2927>. The current scoping review has since been updated.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Author details

¹Sheffield Centre for Health and Related Research (SCHARR), University of Sheffield, Sheffield, UK.

Received: 7 February 2024 Accepted: 27 December 2024

Published online: 08 January 2025

References

1. Organization WH. Global status report on noncommunicable diseases. Geneva: World Health Organization; 2014.
2. Grillo A, Salvi L, Coruzzi P, Salvi P, Parati G. Sodium intake and hypertension. *Nutrients*. 2019;11(9):1970.
3. Miller PM, Anton RF, Egan BM, Basile J, Nguyen SA. Excessive alcohol consumption and hypertension: clinical implications of current research. *J Clin Hypertens (Greenwich)*. 2005;7(6):346–51.
4. Everest G, Marshall L, Fraser C, Briggs A. Addressing the leading risk factors for ill health: a review of government policies tackling smoking, poor diet, physical inactivity and harmful alcohol use in England. The Health Foundation; 2022. <https://doi.org/10.37829/HF-2022-P10>.
5. Kato H, Ikeda N, Sugiyama T, Nomura M, Yoshita K, Nishi N. Use of simulation models in health economic evaluation studies of dietary salt-reduction policies for cardiovascular disease prevention. [*Nihon Koshu Eisei Zasshi*] *Jpn J Public Health*. 2021;68(9):631–43.
6. Emmert-Fees KMF, Karl FM, von Philipsborn P, Rehfuess EA, Laxy M. Simulation modeling for the economic evaluation of Population-based dietary policies: a systematic scoping review. *Adv Nutr*. 2021;12(5):1957–95.
7. Bardach AE, Alcaraz AO, Ciapponi A, Garay OU, Riviere AP, Palacios A, et al. Alcohol consumption's attributable disease burden and cost-effectiveness of targeted public health interventions: a systematic review of mathematical models. *BMC Public Health*. 2019;19(1):1378.
8. Dötsch-Klerk M, Bruins MJ, Detzel P, et al. Modelling health and economic impact of nutrition interventions: a systematic review. *Eur J Clin Nutr*. 2023;77(4):413–26. <https://doi.org/10.1038/s41430-022-01199-y>.
9. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for scoping reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med*. 2018;169(7):467–73.
10. Arksey HOML. Scoping studies: towards a Methodological Framework. *Int J Social Res Methodol Theory Pract*. 2005;8(1):19–32.
11. Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. *Health Econ*. 2006;15(12):1295–310.
12. EED NC. NHS CRD EED search filter for economic evaluations. Available from: www.crd.york.ac.uk/crdweb/searchstrategies.asp.
13. Unal B, Capewell S, Critchley JA. Coronary heart disease policy models: a systematic review. *BMC Public Health*. 2006;6:213.
14. Hoang VP, Shanahan M, Shukla N, Perez P, Farrell M, Ritter A. A systematic review of modelling approaches in economic evaluations of health interventions for drug and alcohol problems. *BMC Health Serv Res*. 2016;16:127.
15. Drummond MSM, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015.
16. Briggs AD, Wolstenholme J, Blakely T, Scarborough P. Choosing an epidemiological model structure for the economic evaluation of non-communicable disease public health interventions. *Popul Health Metr*. 2016;14:17.
17. Brennan A, Angus C, Pryce R, Buykx P, Henney M, Gillespie D, et al. Effectiveness of subnational implementation of minimum unit price for alcohol: policy appraisal modelling for local authorities in England. *Addiction*. 2022;118(5):819–33.
18. Gibbs N, Angus C, Dixon S, Charles DH, Meier PS, Boachie MK, et al. Equity impact of minimum unit pricing of alcohol on household health and finances among rich and poor drinkers in South Africa. *BMJ Glob Health*. 2022;7(1):e007824.

19. Brennan A, Angus C, Pryce R, Buykx P, Henney M, Gillespie D et al. Potential effects of minimum unit pricing at local authority level on alcohol-attributed harms in North West and North East England: a modelling study. *Public Health Research*. Southampton (UK). 2021.
20. Robinson E, Nguyen P, Jiang H, Livingston M, Ananthapavan J, Lal A, et al. Increasing the price of alcohol as an obesity prevention measure: the potential cost-effectiveness of introducing a uniform volumetric tax and a minimum floor price on alcohol in Australia. *Nutrients*. 2020;12(3):603.
21. Jiang H, Room R, Livingston M, Callinan S, Brennan A, Doran C, et al. The effects of alcohol pricing policies on consumption, health, social and economic outcomes, and health inequality in Australia: a protocol of an epidemiological modelling study. *BMJ open*. 2019;9(6):e029918.
22. Cobiac LJ, Mizdrak A, Wilson N. Cost-effectiveness of raising alcohol excise taxes to reduce the injury burden of road traffic crashes. *Injury Prevention: J Int Soc Child Adolesc Injury Prev*. 2019;25(5):421–7.
23. Angus C, Thomas C, Anderson P, Meier PS, Brennan A. Estimating the cost-effectiveness of brief interventions for heavy drinking in primary health care across Europe. *Eur J Pub Health*. 2017;27(2):345–51.
24. Galarraga O, Gao B, Gakinya BN, Klein DA, Wamai RG, Sidle JE, et al. Task-shifting alcohol interventions for HIV+ persons in Kenya: a cost-benefit analysis. *BMC Health Serv Res*. 2017;17(1):239.
25. Zur RM, Zaric GS. A microsimulation cost-utility analysis of alcohol screening and brief intervention to reduce heavy alcohol consumption in Canada. *Addiction (Abingdon England)*. 2016;111(5):817–31.
26. Kessler J, Ruggles K, Patel A, Nucifora K, Li L, Roberts MS, et al. Targeting an alcohol intervention cost-effectively to persons living with HIV/AIDS in East Africa. *Alcoholism Clin Exper Research*. 2015;39(11):2179–88.
27. Angus C, Scafato E, Ghirini S, Torbica A, Ferre F, Struzzo P, et al. Cost-effectiveness of a programme of screening and brief interventions for alcohol in primary care in Italy. *BMC Fam Pract*. 2014;15: 26.
28. Brennan A, Meng Y, Holmes J, Hill-McManus D, Meier PS. Potential benefits of minimum unit pricing for alcohol versus a ban on below cost selling in England 2014: modelling study. *BMJ*. 2014;349:g5452.
29. Holm AL, Veerman L, Cobiac L, Ekholm O, Diderichsen F. Cost-effectiveness of preventive interventions to reduce alcohol consumption in Denmark. *PLoS ONE*. 2014;9(2): e88041.
30. Holm AL, Veerman L, Cobiac L, Ekholm O, Diderichsen F. Cost-effectiveness of changes in alcohol taxation in Denmark: a modelling study. *Cost Eff Resour Alloc*. 2014;12(1):1.
31. Ditsuwon V, Lennert Veerman J, Bertram M, Vos T. Cost-effectiveness of interventions for reducing road traffic injuries related to driving under the influence of alcohol. *Value Health*. 2013;16(1):23–30.
32. Purshouse RC, Brennan A, Rafia R, Latimer NR, Archer RJ, Angus CR, et al. Modelling the cost-effectiveness of alcohol screening and brief interventions in primary care in England. *Alcohol and alcoholism (Oxford, Oxfordshire)*. 2013;48(2):180–8.
33. Doran CM, Byrnes JM, Cobiac LJ, Vandenberg B, Vos T. Estimated impacts of alternative Australian alcohol taxation structures on consumption, public health and government revenues. *Med J Aust*. 2013;199(9):619–22.
34. Popova S, Patra J, Sarnocinska-Hart A, Gnam WH, Giesbrecht N, Rehm J. Cost of privatisation versus government alcohol retailing systems: Canadian example. *Drug Alcohol Rev*. 2012;31(1):4–12.
35. Magnus A, Cadilhac D, Sheppard L, Cumming T, Pearce D, Carter R. The economic gains of achieving reduced alcohol consumption targets for Australia. *Am J Public Health*. 2012;102(7):1313–9.
36. Navarro HJ, Shakeshaft A, Doran CM, Petrie DJ. The potential cost-effectiveness of general practitioner delivered brief intervention for alcohol misuse: evidence from rural Australia. *Addict Behav*. 2011;36(12):1191–8.
37. Cadilhac DA, Magnus A, Sheppard L, Cumming TB, Pearce DC, Carter R. The societal benefits of reducing six behavioural risk factors: an economic modelling study from Australia. *BMC Public Health*. 2011;11(100968562):483.
38. Purshouse RC, Meier PS, Brennan A, Taylor KB, Rafia R. Estimated effect of alcohol pricing policies on health and health economic outcomes in England: an epidemiological model. *Lancet*. 2010;375(9723):1355–64.
39. Barbosa C, Taylor B, Godfrey C, Rehm J, Parrott S, Drummond C. Modelling lifetime QALYs and health care costs from different drinking patterns over time: a Markov model. *Int J Methods Psychiatr Res*. 2010;19(2):97–109.
40. Byrnes JM, Cobiac LJ, Doran CM, Vos T, Shakeshaft AP. Cost-effectiveness of volumetric alcohol taxation in Australia. *Med J Australia*. 2010;192(8):439–43.
41. Tariq L, van den Berg M, Hoogenveen RT, van Baal PH. Cost-effectiveness of an opportunistic screening programme and brief intervention for excessive alcohol use in primary care. *PLoS ONE*. 2009;4(5):e5696.
42. Cobiac L, Vos T, Doran C, Wallace A. Cost-effectiveness of interventions to prevent alcohol-related disease and injury in Australia. *Addiction (Abingdon England)*. 2009;104(10):1646–55.
43. van den Berg M, van Baal PH, Tariq L, Schuit AJ, de Wit GA, Hoogenveen RT. The cost-effectiveness of increasing alcohol taxes: a modelling study. *BMC Med*. 2008;6(101190723):36.
44. Lai T, Habicht J, Reinap M, Chisholm D, Baltussen R. Costs, health effects and cost-effectiveness of alcohol and tobacco control strategies in Estonia. *Health Policy*. 2007;84(1):75–88.
45. Mortimer D, Segal L. Economic evaluation of interventions for problem drinking and alcohol dependence: cost per QALY estimates. *Alcohol Alcohol (Oxf Oxf)*. 2005;40(6):549–55.
46. Chisholm D, Rehm J, Van Ommeren M, Monteiro M. Reducing the global burden of hazardous alcohol use: a comparative cost-effectiveness analysis. *J Stud Alcohol*. 2004;65(6):782–93.
47. Downs SM, Klein JD. Clinical preventive services efficacy and adolescents' risky behaviors. *Arch Pediatr Adolesc Med*. 1995;149(4):374–9.
48. Aminde LN, Wanjau MN, Cobiac LJ, Veerman JL. Estimated impact of achieving the Australian National Sodium reduction targets on blood pressure, chronic kidney disease burden and healthcare costs: a modelling study. *Nutrients*. 2023;15(2):318.
49. Ikeda N, Yamashita H, Hattori J, Kato H, Yoshita K, Nishi N. Reduction of cardiovascular events and related healthcare expenditures through achieving population-level targets of dietary salt intake in Japan: a simulation model based on the National Health and Nutrition Survey. *Nutrients*. 2022;14(17):3606.
50. Thomas C, Breeze P, Cummins S, Cornelsen L, Yau A, Brennan A. The health, cost and equity impacts of restrictions on the advertisement of high fat, salt and sugar products across the transport for London network: a health economic modelling study. *Int J Behav Nutr Phys Act*. 2022;19(1):93.
51. Bates SE, Thomas C, Islam N, Ahern AL, Breeze P, Griffin S, et al. Using health economic modelling to inform the design and development of an intervention: estimating the justifiable cost of weight loss maintenance in the UK. *BMC Public Health*. 2022;22(1):290.
52. Nilson EAF, Pearson-Stuttard J, Collins B, Guzman-Castillo M, Capewell S, O'Flaherty M, et al. Estimating the health and economic effects of the voluntary sodium reduction targets in Brazil: microsimulation analysis. *BMC Med*. 2021;19(1):225.
53. Alonso S, Tan M, Wang C, Kent S, Cobiac L, MacGregor GA, et al. Impact of the 2003 to 2018 Population Salt Intake Reduction Program in England: a modeling study. *Hypertension*. 2021;77(4):1086–94.
54. Aminde LN, Phung HN, Phung D, Cobiac LJ, Veerman JL. Dietary salt reduction, prevalence of hypertension and avoidable Burden of Stroke in Vietnam: modelling the Health and Economic impacts. *Front Public Health*. 2021;9: 682975.
55. Nilson EAF, Metzler AB, Labonté ME, Jaime PC. Modelling the effect of compliance with WHO salt recommendations on cardiovascular disease mortality and costs in Brazil. *PLoS ONE*. 2020;15(7): e0235514.
56. Breeze P, Thomas C, Thokala P, Lafortune L, Brayne C, Brennan A. The impact of including costs and outcomes of dementia in a health economic model to evaluate lifestyle interventions to prevent diabetes and cardiovascular disease. *Med Decis Mak*. 2020;40(7):912–23.
57. Aminde LN, Cobiac L, Veerman JL. Cost-effectiveness analysis of population salt reduction interventions to prevent cardiovascular disease in Cameroon: mathematical modelling study. *BMJ Open*. 2020;10(11): e041346.
58. Mytton OT, Boyland E, Adams J, Collins B, O'Connell M, Russell SJ, et al. The potential health impact of restricting less-healthy food and beverage advertising on UK television between 05.30 and 21.00 hours: a modelling study. *PLoS Med*. 2020;17(10):e1003212.

59. Blakely T, Cleghorn C, Mizdrak A, Waterlander W, Nghiem N, Swinburn B, et al. The effect of food taxes and subsidies on population health and health costs: a modelling study. *Lancet Public Health*. 2020;5(7):e404-13.
60. Lavery AA, Kypridemos C, Seferidi P, Vamos EP, Pearson-Stuttard J, Collins B, et al. Quantifying the impact of the Public Health Responsibility Deal on salt intake, cardiovascular disease and gastric cancer burdens: interrupted time series and microsimulation study. *J Epidemiol Community Health*. 2019;73(9):881-7.
61. Collins B, Kypridemos C, Pearson-Stuttard J, Huang Y, Bandosz P, Wilde P, et al. FDA Sodium reduction targets and the Food Industry: are there incentives to Reformulate? Microsimulation cost-effectiveness analysis. *Milbank Q*. 2019;97(3):858-80.
62. Briggs ADM, Wolstenholme J, Scarborough P. Estimating the cost-effectiveness of salt reformulation and increasing access to leisure centres in England, with PRIMetime CE model validation using the AdvISHE tool. *BMC Health Serv Res*. 2019;19(1):489.
63. Kypridemos C, Collins B, McHale P, Bromley H, Parvulescu P, Capewell S, et al. Future cost-effectiveness and equity of the NHS Health Check cardiovascular disease prevention programme: Microsimulation modelling using data from Liverpool, UK. *PLoS Med*. 2018;15(5): e1002573.
64. Basu S, Yudkin JS, Berkowitz SA, Jawad M, Millett C. Reducing chronic disease through changes in food aid: a microsimulation of nutrition and cardiometabolic disease among Palestinian refugees in the Middle East. *PLoS Med*. 2018;15(11):e1002700.
65. Pearson-Stuttard J, Kypridemos C, Collins B, Mozaffarian D, Huang Y, Bandosz P, et al. Estimating the health and economic effects of the proposed US Food and Drug Administration voluntary sodium reformulation: Microsimulation cost-effectiveness analysis. *PLoS Med*. 2018;15(4): e1002551.
66. Brown V, Ananthapavan J, Veerman L, Sacks G, Lal A, Peeters A, et al. The potential cost-effectiveness and equity impacts of restricting television advertising of unhealthy food and beverages to Australian children. *Nutrients*. 2018;10(5):622.
67. Li X, Jan S, Yan LL, Hayes A, Chu Y, Wang H, et al. Cost and cost-effectiveness of a school-based education program to reduce salt intake in children and their families in China. *PLoS ONE*. 2017;12(9): e0183033.
68. Cobiaci LJ, Tam K, Veerman L, Blakely T. Taxes and Subsidies for Improving Diet and Population Health in Australia: a cost-effectiveness modelling study. *PLoS Med*. 2017;14(2):e1002232.
69. Webb M, Fahimi S, Singh GM, Khatibzadeh S, Micha R, Powles J, et al. Cost effectiveness of a government supported policy strategy to decrease sodium intake: global analysis across 183 nations. *BMJ (Clinical Res ed)*. 2017;356:8900488 bmj, 101090866:i6699.
70. Wang M, Moran AE, Liu J, Coxson PG, Penko J, Goldman L, et al. Projected impact of Salt Restriction on Prevention of Cardiovascular Disease in China: a modeling study. *PLoS ONE*. 2016;11(2):e0146820.
71. Watkins DA, Olson ZD, Verguet S, Nugent RA, Jamison DT. Cardiovascular disease and impoverishment averted due to a salt reduction policy in South Africa: an extended cost-effectiveness analysis. *Health Policy Plann*. 2016;31(1):75-82.
72. Wilson N, Nghiem N, Eyles H, Mhurchu CN, Shields E, Cobiaci LJ, et al. Modeling health gains and cost savings for ten dietary salt reduction targets. *Nutr J*. 2016;15:44.
73. Nghiem N, Blakely T, Cobiaci LJ, Cleghorn CL, Wilson N. The health gains and cost savings of dietary salt reduction interventions, with equity and age distributional aspects. *BMC Public Health*. 2016;16:423.
74. Wilcox ML, Mason H, Fouad FM, Rastam S, al Ali R, Page TF, et al. Cost-effectiveness analysis of salt reduction policies to reduce coronary heart disease in Syria, 2010-2020. *Int J Public Health*. 2015;60(Suppl 1):S23-30.
75. Nghiem N, Blakely T, Cobiaci LJ, Pearson AL, Wilson N. Health and economic impacts of eight different dietary salt reduction interventions. *PLoS ONE*. 2015;10(4): e0123915.
76. Mason H, Shoaibi A, Ghandour R, O'Flaherty M, Capewell S, Khatib R, et al. A cost effectiveness analysis of salt reduction policies to reduce coronary heart disease in four Eastern Mediterranean countries. *PLoS ONE*. 2014;9(1):e84445.
77. Collins M, Mason H, O'Flaherty M, Guzman-Castillo M, Critchley J, Capewell S. An economic evaluation of salt reduction policies to reduce coronary heart disease in England: a policy modeling study. *Value Health*. 2014;17(5):517-24.
78. Ortegon M, Lim S, Chisholm D, Mendis S. Cost effectiveness of strategies to combat cardiovascular disease, diabetes, and tobacco use in sub-saharan Africa and South East Asia: mathematical modelling study. *BMJ*. 2012;344: e607.
79. Ferrante D, Konfino J, Mejia R, Coxson P, Moran A, Goldman L, et al. The cost-utility ratio of reducing salt intake and its impact on the incidence of cardiovascular disease in Argentina. *Rev Panam Salud Publ = Pan Am J Public Health*. 2012;32(4):274-80.
80. Cobiaci LJ, Magnus A, Lim S, Barendregt JJ, Carter R, Vos T. Which interventions offer best value for money in primary prevention of cardiovascular disease? *PLoS ONE*. 2012;7(7): e41842.
81. Doddhia H, Phillips K, Zannou MI, Airolidi M, Bevan G. Modelling the impact on avoidable cardiovascular disease burden and costs of interventions to lower SBP in the England population. *J Hypertens*. 2012;30(1):217-26.
82. Barton P, Andronis L, Briggs A, McPherson K, Capewell S. Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study. *BMJ (Clinical Res ed)*. 2011;343(8900488, bmj, 101090866):d4044.
83. Ha DA, Chisholm D. Cost-effectiveness analysis of interventions to prevent cardiovascular disease in Vietnam. *Health Policy Plann*. 2011;26(3):210-22.
84. Martikainen JA, Soini EJ, Laaksonen DE, Niskanen L. Health economic consequences of reducing salt intake and replacing saturated fat with polyunsaturated fat in the adult Finnish population: estimates based on the FINRISK and FINDIET studies. *Eur J Clin Nutr*. 2011;65(10):1148-55.
85. Rubinstein A, Colantonio L, Bardach A, Caporale J, Marti SG, Kopitowski K, et al. Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina. *BMC Public Health*. 2010;10: 627.
86. Smith-Spangler CM, Juusola JL, Enns EA, Owens DK, Garber AM. Population strategies to decrease sodium intake and the burden of cardiovascular disease: a cost-effectiveness analysis. *Ann Intern Med*. 2010;152(8):481-7 w170-3.
87. Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood JM, Pletcher MJ, et al. Projected effect of dietary salt reductions on future cardiovascular disease. *N Engl J Med*. 2010;362(7):590-9.
88. Cobiaci LJ, Vos T, Veerman JL. Cost-effectiveness of interventions to reduce dietary salt intake. *Heart*. 2010;96(23):1920-5.
89. Palar K, Sturm R. Potential societal savings from reduced sodium consumption in the U.S. adult population. *Am J Health Promotion*. 2009;24(1):49-57.
90. Dall TM, Fulgoni VL 3, Zhang Y, Reimers KJ, Packard PT, Astwood JD. Potential health benefits and medical cost savings from calorie, sodium, and saturated fat reductions in the American diet. *Am J Health Promot*. 2009;23(6):412-22.
91. Akkazieva BCD, Akunov N, Jakob M. The health effects and costs of the interventions to control cardiovascular diseases in Kyrgyzstan. 2009; policy research paper no. 60(Bishkek: Health Policy Analysis Center).
92. Rubinstein A, Garcia Marti S, Souto A, Ferrante D, Augustovski F. Generalized cost-effectiveness analysis of a package of interventions to reduce cardiovascular disease in Buenos Aires, Argentina. *Cost Effectiveness and Resource Allocation*. 2009;7((Rubinstein, Garcia Marti, Souto, Ferrante, Augustovski) IECS, Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina(Rubinstein, Augustovski) Division of Family and Community Medicine, Hospital Italiano de Buenos Aires, Buenos Ai):10.
93. Asaria P, Chisholm D, Mathers C, Ezzati M, Beaglehole R. Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use. *Lancet (London England)*. 2007;370(9604):2044-53.
94. Murray CJL, Lauer JA, Hutubessy RCW, Niessen L, Tomijima N, Rodgers A, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. *Lancet (London England)*. 2003;361(9359):717-25.
95. Selmer RM, Kristiansen IS, Haglerod A, Graff-Iversen S, Larsen HK, Meyer HE, et al. Cost and health consequences of reducing the population intake of salt. *J Epidemiol Community Health*. 2000;54(9):697-702.

96. Bertram MY, Chisholm D, Watts R, Waqanivalu T, Prasad V, Varghese C. Cost-effectiveness of Population Level and Individual Level interventions to combat non-communicable disease in Eastern Sub-saharan Africa and South East Asia: a WHO-CHOICE analysis. *Int J Health Policy Manage*. 2021;10(11):724–33.
97. Cheatley J, Aldea A, Lerouge A, Devaux M, Vuik S, Cecchini M. Tackling the cancer burden: the economic impact of primary prevention policies. *Mol Oncol*. 2021;15(3):779–89.
98. Salomon JA, Carvalho N, Gutierrez-Delgado C, Orozco R, Mancuso A, Hogan DR, et al. Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis. *BMJ* (Clinical research ed). 2012;344(8900488, bmj, 101090866): e355.
99. Kontis V, Mathers CD, Rehm J, Stevens GA, Shield KD, Bonita R, et al. Contribution of six risk factors to achieving the 25 × 25 non-communicable disease mortality reduction target: a modelling study. *Lancet*. 2014;384(9941):427–37.
100. Lauer JA, Rohrich K, Wirth H, Charette C, Gribble S, Murray CJ. PopMod: a longitudinal population model with two interacting disease states. *Cost Eff Resour Alloc*. 2003;1(1):6.
101. Hutubessy R, Chisholm D, Edejer TT. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. *Cost Eff Resour Alloc*. 2003;1(1):8.
102. Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, et al. Making Choices in Health : WHO Guide to Cost Effectiveness Analysis. Geneva: World Health Organization; 2003. p. 2003.
103. Watson P, Preston L, Squires H, Chilcott J, Brennan A. Modelling the economics of type 2 diabetes mellitus prevention: a literature review of methods. *Appl Health Econ Health Policy*. 2014;12(3):239–53.
104. Blakely T, Moss R, Collins J, Mizdrak A, Singh A, Carvalho N, et al. Proportional multistate lifetable modelling of preventive interventions: concepts, code and worked examples. *Int J Epidemiol*. 2020;49(5):1624–36.
105. Briggs ADM, Cobiac LJ, Wolstenholme J, Scarborough P, PRIMetime CE. A multistate life table model for estimating the cost-effectiveness of interventions affecting diet and physical activity. *BMC Health Serv Res*. 2019;19(1):485.
106. Brennan A, Meier P, Purshouse R, Rafia R, Meng Y, Hill-Macmanus D, et al. The Sheffield Alcohol Policy Model - A Mathematical description. *Health Econ*. 2015;24(10):1368–88.
107. Krijkamp EM, Alarid-Escudero F, Enns EA, Jalal HJ, Hunink MGM, Pechlivanoglou P. Microsimulation Modeling for Health Decision Sciences using R: a Tutorial. *Med Decis Mak*. 2018;38(3):400–22.
108. Bertram MY, Lauer JA, Stenberg K, Edejer TTT. Methods for the Economic Evaluation of Health Care Interventions for Priority Setting in the Health System: an Update from WHO CHOICE. *Int J Health Policy Manag*. 2021;10(11):673–7.
109. Mensah J, Thomas C, Akparibo R, Brennan A. SA18 public health economic modelling in evaluations of salt and alcohol policies: a scoping review. *Value Health*. 2023;26(12):S544.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.